Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Related Keywords

Texas ,United States ,Jim Kastenmayer ,Aeglea Biotherapeutics ,Michael Hanley ,Russellj Cox ,Anthony Quinn ,Prnewswire Aeglea Biotherapeutics Inc ,Nasdaq ,Anthony ,Prioritizing Resources ,Ongoing Phase ,Interim Clinical Data Expected ,Board Member ,Stepped Down ,His Current Positions ,Extend Runway ,Classical Homocystinuria ,Drug Designation ,Pediatric Disease ,Rare Pediatric Disease ,Breakthrough Therapy ,Nc ,